Usually exceptionally good results "dictates" discontinuing the trial and putting all patients on the real drug. Likewise, serious adverse effects can result in discontinuing the trial. The latter is highly important and relevant here (and some do not quite appreciate it), as a serious adverse effect is at the minimum to be repoerted to the blind parties. Hence "no news is good news" applies, and the least we can say here is that drug is safe. AIMO.
Ann: Immutep Corporate Presentation, page-119
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
0.015(5.36%) |
Mkt cap ! $428.5M | |||
| Open | High | Low | Value | Volume |
| 28.5¢ | 30.5¢ | 28.0¢ | $833.4K | 2.824M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 388130 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.0¢ | 39940 | 3 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |